$IMUX News

Immunic, Inc. (IMUX) Presents at 10th Joint ACTRIMS-ECTRIMS Meeting - MSToronto2026 - Slideshow

Cantor Fitzgerald Initiates Coverage On Immunic with Overweight Rating

Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting

Immunic to showcase phase 2 long-term MS disability data at MSToronto2026

Immunic adds new Chief People Officer ahead of Phase 3 readout

Immunic Appoints Jaa Roberson as Chief People Officer

Immunic to present four vidofludimus calcium abstracts at MSToronto2026

Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting

Immunic Announces Acceptance Of Four Abstracts At MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting

Immunic, Inc. (IMUX) Discusses R&D Advances and Future Directions in Relapsing Multiple Sclerosis Transcript

Immunic, Inc. (IMUX) Presents at EFMC Medicinal Chemistry 2026 Basel - Slideshow

Wedbush Reiterates Outperform on Immunic, Maintains $45 Price Target

HC Wainwright & Co. Reiterates Buy on Immunic, Maintains $22 Price Target

Immunic, Inc. (IMUX) Discusses R&D Advances and Future Directions in Relapsing Multiple Sclerosis - Slideshow

Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026

Immunic appoints Chitrang Davé as chief data and digital officer

Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating

Wedbush Initiates Coverage On Immunic with Outperform Rating, Announces Price Target of $45

Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?

Immunic advances MS drug toward key Phase 3 data, expects results by year-end